14.17

3.20% 0.44

Neogenomics Inc (NEO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NEO? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$13.73

Offen:

$13.69

24-Stunden-Volumen:

7.13M

Relative Volume:

2.94

Marktkapitalisierung:

$1.85B

Einnahmen:

$745.97M

Nettoeinkommen (Verlust:

$-99.21M

KGV:

-18.33

EPS:

-0.7729

Netto-Cashflow:

$-5.09M

1W Leistung:

+27.31%

1M Leistung:

+52.86%

6M Leistung:

+15.39%

1J Leistung:

+97.91%

1-Tages-Spanne:

$13.60

$14.23

1-Wochen-Bereich:

$10.96

$14.23

52-Wochen-Spanne:

$4.72

$14.23

Neogenomics Inc Stock (NEO) Company Profile

Firmenname

Neogenomics Inc

Sektor

Healthcare (1096)

Branche

Diagnostics & Research (48)

Telefon

(239) 768-0600

Adresse

9490 NEOGENOMICS WAY, FORT MYERS, FL

Mitarbeiter

2,500

Twitter

@NeoGenomics

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

NEO's Discussions on Twitter

Compare NEO vs TMO, DHR, IDXX, A, NTRA

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NEO Neogenomics Inc	14.17	1.79B	745.97M	-99.21M	-5.09M	-0.7729
TMO Thermo Fisher Scientific Inc	513.03	187.95B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	196.19	136.75B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	551.50	43.78B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	136.01	38.27B	7.23B	1.41B	1.09B	4.979
NTRA Natera Inc	261.91	37.34B	2.50B	-226.32M	71.51M	-1.6412

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-30	Herabstufung	BTIG Research	Buy → Neutral
2025-07-29	Herabstufung	William Blair	Outperform → Mkt Perform
2025-05-15	Eingeleitet	Guggenheim	Neutral
2025-04-30	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-01-13	Herabstufung	The Benchmark Company	Buy → Hold
2024-12-10	Eingeleitet	Jefferies	Buy
2024-05-01	Fortgesetzt	Craig Hallum	Buy
2023-12-29	Bestätigt	BTIG Research	Buy
2023-08-21	Hochstufung	Stephens	Equal-Weight → Overweight
2023-05-16	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-05-09	Hochstufung	BTIG Research	Neutral → Buy
2023-02-24	Hochstufung	The Benchmark Company	Hold → Buy
2023-02-01	Hochstufung	Needham	Hold → Buy
2022-08-26	Herabstufung	The Benchmark Company	Buy → Hold
2022-08-22	Herabstufung	Needham	Buy → Hold
2022-06-03	Eingeleitet	Piper Sandler	Overweight
2022-03-29	Herabstufung	BofA Securities	Buy → Neutral
2022-03-29	Herabstufung	Stephens	Overweight → Equal-Weight
2022-01-18	Fortgesetzt	Stephens	Overweight
2021-12-16	Eingeleitet	Cowen	Outperform
2021-11-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Hochstufung	Raymond James	Mkt Perform → Outperform
2021-06-03	Eingeleitet	Goldman	Buy
2021-02-25	Fortgesetzt	Needham	Buy
2021-02-25	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-01-28	Eingeleitet	Truist	Buy
2020-12-11	Fortgesetzt	BTIG Research	Buy
2020-10-28	Bestätigt	Needham	Buy
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-08-28	Eingeleitet	Guggenheim	Buy
2020-07-29	Bestätigt	Needham	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Buy
2020-04-21	Fortgesetzt	Stephens	Overweight
2020-03-02	Fortgesetzt	Craig Hallum	Buy
2020-02-28	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Bestätigt	Needham	Buy
2019-05-01	Bestätigt	Needham	Buy
2019-03-29	Bestätigt	Needham	Buy
2019-01-03	Eingeleitet	Needham	Buy
2018-10-24	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Eingeleitet	Leerink Partners	Outperform
2018-05-02	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Herabstufung	BTIG Research	Buy → Neutral
2017-08-24	Eingeleitet	Gabelli & Co	Buy
2016-12-15	Eingeleitet	Cantor Fitzgerald	Overweight

Alle ansehen

Neogenomics Inc Aktie (NEO) Neueste Nachrichten

08:08 AM

Enterprise value to revenue forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of NeoGenomics, Inc. – LSX:120159 - TradingView

Jun 26, 2026

A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack - Yahoo Finance

Jun 26, 2026

Jun 25, 2026

NEO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Neogenomics stock hits 52-week high at 13.74 USD - Investing.com UK

Jun 25, 2026

Neogenomics stock hits 52-week high at 13.74 USD By Investing.com - Investing.com South Africa

Jun 25, 2026

NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants - Stock Titan

Jun 25, 2026

NeoGenomics (NEO) director Carolyn Starrett files initial Form 3 - Stock Titan

Jun 25, 2026

NeoGenomics, Inc. Announces Appointment of Carolyn Starrett to Board of Directors - marketscreener.com

Jun 25, 2026

NeoGenomics Taps AI Veteran for Board, Signaling Data-Driven Future - BriefGlance

Jun 25, 2026

NeoGenomics Appoints Carolyn Starrett to Board of Directors - citybiz

Jun 25, 2026

NeoGenomics appoints Carolyn Starrett to board of directors - Investing.com

Jun 25, 2026

NeoGenomics appoints Carolyn Starrett to board of directors By Investing.com - Investing.com Canada

Jun 25, 2026

NeoGenomics appoints Carolyn S. Starrett to its Board - TradingView

Jun 25, 2026

Carolyn Starrett joins NeoGenomics (NEO) board, expanding oncology and AI expertise - Stock Titan

Jun 25, 2026